Finance Director
We’re looking for a finance leader who thrives in fast-paced, high-growth environments to lead and scale our finance operations. As the go-to person for all financial matters, you’ll play a key role in both strategy and execution, working closely with founders,...
Closing meeting with the LiquiDx consortium
On 18th September 2025, the LiquiDx consortium gathered at the Biobanco del Sistema Sanitario Público de Andalucía (BBSSPA) facilities in Granada for the final face-to-face meeting of the project. The sessions, which were also transmitted by videoconference, served to...Cloud & Information Technology Manager
Flomics is a fast-growing biotech company founded in 2018 in Barcelona. We are developing a revolutionary liquid biopsy test for the early detection of cancer, based on the analysis of cell-free RNA in blood. By combining cutting-edge genomics with advanced...Bioinformatics Senior Scientist
Flomics is a fast-growing biotech company founded in 2018 in Barcelona. We are developing a revolutionary liquid biopsy test for the early detection of cancer, based on the analysis of cell-free RNA in blood. By combining cutting-edge genomics with advanced...Bioinformatics Lead Scientist
Flomics is a fast-growing biotech company founded in 2018 in Barcelona. We are developing a revolutionary liquid biopsy test for the early detection of cancer, based on the analysis of cell-free RNA in blood. By combining cutting-edge genomics with advanced...
Flomics Tackles Lung Cancer Relapse Detection with RNA-Based Liquid Biopsy in European Project LUMINA
Flomics participates in LUMINA, a Eurostars-funded project to detect lung cancer recurrence through liquid biopsy and artificial intelligence Barcelona – July 8, 2025 – Flomics Biotech is part of the international consortium led by RenovaroCube that has...
Flomics Breakthrough in Liquid Biopsy: RNA & AI Enable Multicancer Early Detection
Flomics new study shows a cancer predictive power of 92% and high sensitivity in the early detection of five cancer types: colorectal, lung, breast, prostate and pancreas. Barcelona – January 31, 2025 – Flomics presented last week at the Liquid Biopsy...
Third face-to-face meeting of the LiquiDx project consortium
The LiquiDx consortium gathered for its third annual coordination meeting on 31st October 2024 at Leitat’s facilities at the Parc Cientific de Barcelona. The meeting reviewed the project’s progress toward developing a cutting-edge RNA-based blood diagnostic tool to...
First Freedom-to-operate study completed with the support of ACCIÓ
Flomics Biotech conducted an extensive Freedom-To-Operate (FTO) study in collaboration with ZBM Patents, an expert external IP firm. The study analysed 246 patent families related to cfRNA-based liquid biopsy technologies and confirmed that Flomics’ approach...
Successful Crowdfunding Campaign with Capital Cell
We have officially closed our crowdfunding campaign with Capital Cell! Running from June 18 to July 12, 2024, this campaign has been a testament to the strong belief and support we have toward our mission, proposal, and work. This milestone consolidates another step...